

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

AF	APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTO	ORNEY DOCKET NO.	
	09/581.3	tor os/to/	00 FUCCSAWA	••• •	20 00_02108	
Г			HM22/0917	EXA	MINER	
		WENDEROTH LIND & PONACK 2033 K STREET NW			FREDMAN.I	
	SUITE 80			ART UNIT	PAPER NUMBER	
		ON DC 20006		1695	5	
				DATE MAILED:	09/17/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

Examiner

Applicant(s)

09/581,402

Jeffrey Fredman

Fujisawa et al

Art Unit 1655



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address		
	for Reply			
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET WAILING DATE OF THIS COMMUNICATION.			
af	ter SIX (6) MONTHS from the mailing date of this communic	FR 1.136 (a). In no event, however, may a reply be timely filed ation.		
- If the	e period for reply specified above is less than thirty (30) days e considered timely.	, a reply within the statutory minimum of thirty (30) days will		
- If NO	period for reply is specified above, the maximum statutory	period will apply and will expire SIX (6) MONTHS from the mailing date of this		
- Failu	ommunication. re to reply within the set or extended period for reply will, by	statute, cause the application to become ABANDONED (35 U.S.C. § 133).		
	reply received by the Office later than three months after the grned patent term adjustment. See 37 CFR 1.704(b).	e mailing date of this communication, even if timely filed, may reduce any		
Status	,			
1) 🗆	Responsive to communication(s) filed on	·		
2a) 🗌	This action is FINAL . 2b) 🔀 This act	tion is non-final.		
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is orte Quayle, 1935 C.D. 11; 453 O.G. 213.		
Disposi	tion of Claims			
4) 💢	Claim(s) <u>1-15</u>	is/are pending in the application.		
4	4a) Of the above, claim(s)	is/are withdrawn from consideration.		
5) 🗆	Claim(s)	is/are allowed.		
6) 🗆	Claim(s)	is/are rejected.		
7) 🗆	Claim(s)	is/are objected to.		
8) 💢	Claims <u>1-15</u>	are subject to restriction and/or election requirement.		
Applica	ation Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)	The drawing(s) filed on is/are	objected to by the Examiner.		
11)	The proposed drawing correction filed on	is: a) □ approved b) □ disapproved.		
12)	The oath or declaration is objected to by the Exam			
Priority	under 35 U.S.C. § 119			
	Acknowledgement is made of a claim for foreign p	riority under 35 U.S.C. § 119(a)-(d).		
a) [☐ All b)☐ Some* c)☐ None of:	•		
	1. \square Certified copies of the priority documents have	ve been received.		
	2. \square Certified copies of the priority documents have	ve been received in Application No.		
	application from the International Bure			
*S	ee the attached detailed Office action for a list of th			
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).		
Attachm	nent(s)			
15) 💢 N	lotice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s)		
_	lotice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)		
17) 📙 lr	nformation Disclosure Statement(s) (PTO-1449) Paper No(s).	20 Other:		

Application/Control Number: 09/581,402 Page 2

Art Unit: 1655

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-7,12, 13, drawn to a metalloproteinase inhibitor compound.

Group II, claim(s) 8, drawn to methods of treatment of tissue degradation.

Group III, claim(s) 9-11, 14, drawn to a method of making a inhibitor compound.

Group IV, claim(s) 15, drawn to a compound of Formula III.

2. The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: There is no special technical feature because the invention is not novel over the prior art. In particular, claim 1 is anticipated by Dickens et al, (WO9402447) who teaches a compound with the structure:

Application/Control Number: 09/581,402 Page 3

Art Unit: 1655

This structure anticipates claim 1 (see pages 4-9 and claims 1-17). As a further note, the STN registry search revealed over 100 references prior to 1997 which contained structures that potentially fall within the scope of the claims.

3. Claims 1-15 are generic to a plurality of disclosed patentably distinct species. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

4. A telephone call was made to Lee Cheng on September 14, 2001 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/581,402

Art Unit: 1655

fee required under 37 CFR 1.17(i).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman, Ph.D. whose telephone number is (703) 308-6568.

The examiner is normally in the office between the hours of 6:30 a.m. and 4:00 p.m., and telephone calls either in the early morning or the afternoon are most likely to find the examiner in the office.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Art Unit: 1655

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission via the P.T.O. Fax Center located in Crystal Mall 1. The CM1 Fax Center numbers for Technology Center 1600 are either (703) 305-3014 or (703) 308-4242. Please note that the faxing of such papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Jeffrey Fredman
Primary Patent Examiner
Art Unit 1655

September 14, 2001